Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tagliabue, Elda"'
Autor:
Cataldo A; Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Piovan C; Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Plantamura I; Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., D'Ippolito E; Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Camelliti S; Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Casalini P; Molecular Targeting Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Giussani M; Molecular Targeting Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Déas O; Xentech, Genopole Campus 3, Evry, Paris., Cairo S; Xentech, Genopole Campus 3, Evry, Paris., Judde JG; Xentech, Genopole Campus 3, Evry, Paris., Tagliabue E; Molecular Targeting Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio MV; Start Up Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2018 Jun 15; Vol. 9 (46), pp. 27920-27928. Date of Electronic Publication: 2018 Jun 15 (Print Publication: 2018).
Autor:
Palladini A; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Nicoletti G; Rizzoli Orthopedic Institute, Laboratory of Experimental Oncology, Bologna, Italy., Lamolinara A; Aging Research Centre, 'Gabriele d'Annunzio' University, Chieti, Italy., Dall'Ora M; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Balboni T; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Ianzano ML; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Laranga R; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Landuzzi L; Rizzoli Orthopedic Institute, Laboratory of Experimental Oncology, Bologna, Italy., Giusti V; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Ceccarelli C; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.; Pathology Unit, Policlinico S.Orsola-Malpighi University Hospital, Bologna, Italy., Santini D; Pathology Unit, Policlinico S.Orsola-Malpighi University Hospital, Bologna, Italy., Taffurelli M; Department of Medical and Surgical Sciences of Bologna, Bologna, Italy., Di Oto E; Anatomic Pathology, Department of Biomedical and Neuromotor Sciences, Bellaria Hospital, University of Bologna, Bologna, Italy., Asioli S; Anatomic Pathology, Department of Biomedical and Neuromotor Sciences, Bellaria Hospital, University of Bologna, Bologna, Italy., Amici A; University of Camerino, Camerino, Italy., Pupa SM; Istituto Nazionale Tumori, Milano, Italy., De Giovanni C; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Tagliabue E; Istituto Nazionale Tumori, Milano, Italy., Iezzi M; Aging Research Centre, 'Gabriele d'Annunzio' University, Chieti, Italy., Nanni P; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Lollini PL; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2017 Apr 13; Vol. 8 (33), pp. 54444-54458. Date of Electronic Publication: 2017 Apr 13 (Print Publication: 2017).
Autor:
Turdo F; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Bianchi F; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy., Gasparini P; Tumor Genomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Sandri M; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Sasso M; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., De Cecco L; Functional Genomic Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Forte L; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Casalini P; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Aiello P; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Sfondrini L; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy., Agresti R; Division of Surgical Oncology, Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Carcangiu ML; Division of Breast Anatomy Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Plantamura I; Start-Up Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sozzi G; Tumor Genomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Tagliabue E; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Campiglio M; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2016 Oct 25; Vol. 7 (43), pp. 69649-69665.
Autor:
Cataldo A; Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine and Solid Tumor Biology Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy., Cheung DG; Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine and Solid Tumor Biology Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA., Balsari A; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, Milan, Italy., Coppola V; Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine and Solid Tumor Biology Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA., Iorio MV; Start Up Unit, Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, Milan, Italy., Palmieri D; Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine and Solid Tumor Biology Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA., Croce CM; Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine and Solid Tumor Biology Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Publikováno v:
Oncotarget [Oncotarget] 2016 Jan 05; Vol. 7 (1), pp. 786-97.
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Autor:
Di Modica M; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sfondrini L; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy., Regondi V; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Varchetta S; Department of Infectious Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy., Oliviero B; Department of Infectious Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy., Mariani G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bianchi GV; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Generali D; Dipartimento di Terapia Molecolare e Farmacogenomica, Istituti Ospitalieri di Cremona, Cremona, Italy., Balsari A; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2016 Jan 05; Vol. 7 (1), pp. 255-65.
Autor:
Triulzi T; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Cecco L; Department of Experimental Oncology and Molecular Medicine, Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sandri M; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Prat A; Translational Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Medical Oncology Department, Hospital Clínic i Provincial, Barcelona, Spain., Giussani M; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Paolini B; Department of Pathology, Anatomic Pathology A Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Carcangiu ML; Department of Pathology, Anatomic Pathology A Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Canevari S; Department of Experimental Oncology and Molecular Medicine, Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bottini A; Dipartimento di Terapia Molecolare e Farmacogenomica, Istituti Ospitalieri di Cremona, Italy., Balsari A; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Italy., Menard S; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Generali D; Dipartimento di Terapia Molecolare e Farmacogenomica, Istituti Ospitalieri di Cremona, Italy., Campiglio M; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Cosimo S; Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2015 Sep 29; Vol. 6 (29), pp. 28173-82.